A large number of sensitivity analyses were performed and “largely confirm” the outcomes of the primary analyses.
Limitations include the lack of MRI data, and it was not possible to evaluate the relative safety of treatments.
Dr. Kalincik disclosed ties with Roche, Genzyme, Novartis, Merck, Biogen, WebMD Global, Sanofi, Teva, and BioCSL.